Pathalys Pharma

About:

Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease.

Website: https://pathalys.com

Twitter/X: PathalysPharma

Top Investors: The Carlyle Group, OrbiMed, TCG Crossover, Samsara BioCapital, KB Investment

Description:

Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease. Pathalys' initial focus will be on improving treatment for secondary hyperparathyroidism, which is an unmet need (SHPT). SHPT is a condition in which a disease outside of the parathyroid glands causes all of the parathyroid glands to swell and become hyperactive, producing an excessive amount of parathyroid hormone (PTH).